Compare CINT & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CINT | IPSC |
|---|---|---|
| Founded | 1995 | 2019 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 515.4M | 413.0M |
| IPO Year | 2021 | 2021 |
| Metric | CINT | IPSC |
|---|---|---|
| Price | $3.91 | $2.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $7.35 | $4.25 |
| AVG Volume (30 Days) | 96.0K | ★ 843.0K |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.30 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $109,164,000.00 |
| Revenue This Year | $16.69 | N/A |
| Revenue Next Year | $11.28 | N/A |
| P/E Ratio | $17.94 | ★ N/A |
| Revenue Growth | N/A | ★ 1556.76 |
| 52 Week Low | $3.81 | $0.44 |
| 52 Week High | $6.71 | $2.97 |
| Indicator | CINT | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 36.63 | 49.90 |
| Support Level | N/A | $2.15 |
| Resistance Level | $5.01 | $2.67 |
| Average True Range (ATR) | 0.26 | 0.12 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 14.31 | 48.33 |
CI&T Inc operates as a partner in tech-integrated business solutions, helping organizations address complex challenges by integrating business approach, technology, and artificial intelligence into a single, coherent operating model. It is mainly engaged in the development of customizable software through the implementation of software solutions, including machine learning, artificial intelligence, data analytics, cloud migration and mobility technologies. The company provides technology services to various industry verticals, including Financial Services, Consumer Goods, Technology and Communications, Retail and Industrial Goods, Life Sciences, among others. The majority of the revenue is derived from providing technology services. Geographically, maximum revenue is derived from Brazil.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.